Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$11.62 USD
-0.33 (-2.76%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $11.80 +0.18 (1.55%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CDTX 11.62 -0.33(-2.76%)
Will CDTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDTX
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for CDTX
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
Cidara Therapeutics names Jim Beitel CBO
Cidara Therapeutics just upgraded at H.C. Wainwright, here's why
Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones